Your browser doesn't support javascript.
loading
Clinical applications of a novel poly-L-lactic acid microsphere and hyaluronic acid suspension for facial depression filling and rejuvenation.
Su, Diya; Yang, Wei; He, Tong; Wu, Jiaxu; Zou, Muyan; Liu, Xiaowen; Li, Ruizhi; Wang, Shiwei; Lai, Chen; Wang, Jieqing.
Affiliation
  • Su D; Plastic & Aesthetic Surgery Center, Dalian University Affiliated Xinhua Hospital, Dalian, Liaoning, China.
  • Yang W; Beijing Huaxia Medical Beauty Hospital, Beijing, China.
  • He T; Bejing Engineering Lab of Neo-Biodegradable Materials, Beijing, China.
  • Wu J; Medical Department, Imeik Technology Development Co., Ltd., Beijing, China.
  • Zou M; Medical Department, Imeik Technology Development Co., Ltd., Beijing, China.
  • Liu X; Bejing Engineering Lab of Neo-Biodegradable Materials, Beijing, China.
  • Li R; Bejing Engineering Lab of Neo-Biodegradable Materials, Beijing, China.
  • Wang S; Bejing Engineering Lab of Neo-Biodegradable Materials, Beijing, China.
  • Lai C; Medical Department, Imeik Technology Development Co., Ltd., Beijing, China.
  • Wang J; Shenzhen Key Laboratory of Human Tissue Regeneration and Repair, PKU-HKUST ShenZhen-HongKong Institution, Shenzhen, China.
J Cosmet Dermatol ; 2024 Jul 22.
Article in En | MEDLINE | ID: mdl-39037908
ABSTRACT

BACKGROUND:

Poly L-lactic acid (PLLA) can stimulate fibrous tissue regeneration to exert a filling effect. However, severe inflammatory reactions and unsatisfactory effects remain a concern.

OBJECTIVE:

Herein, we describe the mechanism of action, efficacy, and safety of PLLA microspheres in suspension (PLLA-b-PEG/HA) for facial contouring and soft tissue augmentation.

METHODS:

PLLA-b-PEG/HA, ssynthesized by copolymerization with ethylene glycol, were suspended in hyaluronic acid (HA). Physiological verification was performed using scanning electron microscopy and X-ray computed tomography. PLLA-b-PEG/HA were subcutaneously injected into the dorsal region of 4-month-old rabbits. Ultrasound assessed volumetric capacity at 3 days and 1, 2, 4, and 12 weeks. The inflammatory response, collagen production, and HA degradation were evaluated. A retrospective case series of 10 patients who received PLLA-b-PEG/HA injections was conducted to assess long-term efficacy and safety.

RESULTS:

PLLA-b-PEG exhibited a spherical structure with a smooth surface (20-45 µm diameter). In rabbits, implant site volume increased within 4 weeks, gradually decreasing thereafter. Fibrous capsules, microvessel density, and new collagen fiber formation progressively increased at 4, 12, and 26 weeks after injection. Clinical data demonstrated significant improvements in face contouring at months 3 and 12 after injection. All patients showed improved internal contours based on the Global Aesthetic Improvement Scale. After 12 months, 90% of the patients retained good shaping and support effects with minimal adverse reactions.

CONCLUSIONS:

PLLA-b-PEG/HA demonstrated superior biocompatibility and facial regeneration potential, with outstanding dual collagen-stimulating properties. The clinical efficacy and safety of PLLA-b-PEG/HA have been validated and established as a promising therapeutic option.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Cosmet Dermatol Journal subject: DERMATOLOGIA Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Cosmet Dermatol Journal subject: DERMATOLOGIA Year: 2024 Document type: Article Affiliation country: